Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDXNASDAQ:BCYCNASDAQ:ELVNNASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$3.88-3.8%$4.42$3.21▼$8.06$929.51M0.764.43 million shs1.11 million shsBCYCBicycle Therapeutics$8.28-4.9%$7.99$6.10▼$28.67$572.04M1.6393,127 shs100,309 shsELVNEnliven Therapeutics$18.03+1.6%$18.08$13.30▼$30.03$889.28M1.07260,763 shs57,558 shsLYELLyell Immunopharma$0.41+1.1%$0.45$0.39▼$2.80$119.32M-0.251.03 million shs211,998 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+3.07%+1.77%-26.06%-24.81%-39.03%BCYCBicycle Therapeutics+6.10%+7.41%+5.97%-20.69%-60.18%ELVNEnliven Therapeutics+10.39%+5.78%-4.88%-14.83%-16.83%LYELLyell Immunopharma-2.05%-4.92%-7.06%-43.50%-84.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.6321 of 5 stars4.53.00.04.42.52.50.6BCYCBicycle Therapeutics3.2412 of 5 stars4.41.00.00.01.94.20.6ELVNEnliven Therapeutics2.9798 of 5 stars3.62.00.00.03.44.20.0LYELLyell Immunopharma2.2772 of 5 stars2.80.00.00.02.15.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.90Moderate Buy$10.39168.10% UpsideBCYCBicycle Therapeutics 2.70Moderate Buy$25.00202.11% UpsideELVNEnliven Therapeutics 3.20Buy$37.25106.66% UpsideLYELLyell Immunopharma 1.50Reduce$1.00146.31% UpsideCurrent Analyst Ratings BreakdownLatest BCYC, LYEL, ARDX, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/5/2025BCYCBicycle TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.005/2/2025ARDXArdelyxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/2/2025ARDXArdelyxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$11.005/2/2025BCYCBicycle TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.005/2/2025BCYCBicycle TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.005/2/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.005/2/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/1/2025BCYCBicycle TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$361.71M2.56N/AN/A$0.73 per share5.31BCYCBicycle Therapeutics$25.72M22.28N/AN/A$12.35 per share0.67ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/ALYELLyell Immunopharma$65K1,844.73N/AN/A$2.60 per share0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.22N/A12.50N/A-11.73%-24.87%-10.51%8/7/2025 (Estimated)BCYCBicycle Therapeutics-$180.66M-$3.14N/AN/AN/A-450.64%-27.35%-20.81%8/5/2025 (Estimated)ELVNEnliven Therapeutics-$71.58M-$1.92N/AN/AN/AN/A-29.46%-27.33%8/12/2025 (Estimated)LYELLyell Immunopharma-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)Latest BCYC, LYEL, ARDX, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/13/2025Q1 2025LYELLyell Immunopharma-$0.19-$0.18+$0.01-$0.18N/A$0.01 million5/1/2025Q1 2025ARDXArdelyx-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million5/1/2025Q1 2025BCYCBicycle Therapeutics-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ABCYCBicycle TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx0.874.584.31BCYCBicycle TherapeuticsN/A17.1317.13ELVNEnliven TherapeuticsN/A17.4417.44LYELLyell ImmunopharmaN/A13.4313.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%BCYCBicycle Therapeutics86.15%ELVNEnliven Therapeutics95.08%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%BCYCBicycle Therapeutics22.90%ELVNEnliven Therapeutics29.20%LYELLyell Immunopharma25.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90239.26 million222.88 millionOptionableBCYCBicycle Therapeutics24069.25 million63.18 millionOptionableELVNEnliven Therapeutics5049.07 million34.59 millionOptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableBCYC, LYEL, ARDX, and ELVN HeadlinesRecent News About These CompaniesvenBio Partners LLC Makes New Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 22, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires New Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 19, 2025 | marketbeat.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 17, 2025 | finanznachrichten.deOrbimed Advisors LLC Decreases Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 15, 2025 | marketbeat.comLyell Immunopharma Advances CAR T-Cell Therapy PipelineMay 14, 2025 | tipranks.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 13, 2025 | globenewswire.comForesite Capital Management V LLC Invests $5.21 Million in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 12, 2025 | marketbeat.comAlmitas Capital LLC Takes Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 4, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 3, 2025 | marketbeat.comLyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025May 1, 2025 | globenewswire.comLyell Immunopharma (LYEL) Projected to Post Earnings on MondayApril 30, 2025 | marketbeat.comLyell Immunopharma announces FDA granted RMAT designation to LYL314April 17, 2025 | markets.businessinsider.comWhy Lyell Immunopharma, Inc.’s (LYEL) Stock Is Up 7.22%April 16, 2025 | aaii.comLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaApril 15, 2025 | globenewswire.comCAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisitionApril 8, 2025 | fiercepharma.comLyell Cuts 73 Employees as Part of LA Site ClosureApril 7, 2025 | biospace.comOtis W. Brawley Buys 35,640 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockApril 3, 2025 | insidertrades.comBank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)March 28, 2025 | markets.businessinsider.comIs Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comWhy Lyell Immunopharma, Inc.’s (LYEL) Stock Is Up 20.28%March 20, 2025 | aaii.comFavourable Signals For Lyell Immunopharma: Numerous Insiders Acquired StockMarch 20, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCYC, LYEL, ARDX, and ELVN Company DescriptionsArdelyx NASDAQ:ARDX$3.88 -0.16 (-3.85%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Bicycle Therapeutics NASDAQ:BCYC$8.28 -0.43 (-4.89%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Enliven Therapeutics NASDAQ:ELVN$18.02 +0.29 (+1.61%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Lyell Immunopharma NASDAQ:LYEL$0.41 +0.00 (+1.10%) As of 12:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
